Brief: CASI Pharma Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple Myeloma
10/06/2021 12:33
June 10 (Reuters) - CASI Pharmaceuticals Inc CASI.O :
* CASI PHARMACEUTICALS ANNOUNCES DOSING OF FIRST PATIENT OF
CID-103 IN PHASE 1 CLINICAL TRIAL FOR RELAPSED OR REFRACTORY
MULTIPLE MYELOMA
Source text for Eikon: ID:nPn22yyKBa
Further company coverage: CASI.O
(((Reuters.Briefs@thomsonreuters.com);))
Recent news on CASI Pharmaceuticals
See all newsBrief: Casi Pharmaceuticals Reports The Receipt Of Drug Registration Certificate For Thiotepa In China
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Brief: CASI Pharmaceuticals Inc Reports The Expiration Of Import Drug Registration License For Folotyn® In China
Casi Pharmaceuticals Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary